In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans;Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neoformans

Revista Iberoamericana de Micologia

Volumn 14, Issue 2, 1997, Pages 50-54

  Muñoz, Alfonso Javier Carrillo ^a,c   Tur, Cristina ^a   Estivill, Dolors ^a   Montsant, Lourdes ^a   Carceller, Anna ^a   Hernández Molina, Juan Manuel ^b   Torres Rodríguez, Josep M ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b Hospital de La Inmaculada   (Spain)

^c NONE   (Spain)

Author keywords

Antifungals; Cross resistance; Fluconazole; In vitro susceptibility; Itraconazole; Ketoconazole; Tioconazole; Triazoles

Indexed keywords

EID: 2742551167     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s Eur J Clin Microbiol Infect Dis 1992; 11: 287-291.
2. Ponton J, Quindós G. Las micosis en la década de 1990. Enferm Infec Microbiol Clin 1992;10:385-388.
3. San Blas G Antibióticos antifúngicos. hacia la búsqueda de antibióticos selectives Rev Iberoam Micol 1991;8:24-34.
4. Torres-Rodríguez JM. Estado actual de los antifúngicos de uso sistémico Rev Esp Quimioter 1992;5:162-169.
5. Shadomy S, Espinel-Ingroff A, Cartwright RY. Laboratory studies with antifungal agents: susceptibility tests and bioassays. En. Lennette E, Balows J, Hausler W, Shadomy HJ (Eds). Manual of Clinical Microbiology (4 Ed) Washington DC, American Society for Microbiology, 1985:991-999.
6. Kobayashi GS, Spitzer DE. Testing of organisms for susceptibility to triazoles Is it justified? Eur J Clin Microbiol Infect Dis 1990;8:387-389.
7. Troke PF, Andrews RJ, Pye GW, Richardson K. Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy Rev Infect Dis 1990;12 (Suppl 3): S276-280.
8. Stiller RL, Bennett JE, Scholler HJ, Wall M, Polak A, Stevens DA. Correlation of in vitro susceptibility tests with the in vivo response flucytosine therapy in a systemic candidiasis model. J Infect Dis 1983;147:1070-1077
9. Shadomy S, Pfaller MA. Laboratory studies with antifungal agents susceptibility tests and quantitation in body fluids. En Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (Eds). Manual of Clinical Microbiology, (5 ed) Washington DC, American Society for Microbiology, 19911173-1183.
10. Quindós G. Terapéutica anticandidiásica. Gac Med (Bilbac)1992;89:186-188.
11. Rubio Calvo MC, Gil Tomás J, Benito Ruesca R. Las pruebas in vitro en la evaluación de los agentes antifúngicos. Rev Esp Quimioter 1993;6:21.
12. Hernández-Molina JM, Coque MT, Campos E, Rando C, Leiva EF Estudio de un método automatizado de identificación de levaduras ATB32C. Enferm Infec Microbiol Clin 1992;10:293-295.
13. Casals JB. Tablet sensitivity testing of pathogenic fungi. J Clin Pathol 1979;32:719-722.
14. Sandven P, Bjorneklett A, Maeland A, and the Norvergian Yeast Study Group. Susceptibilites of Norwegian Candida albicans strains to fluconazole emergence of resistance. Antimicrob Agents Chemother. 1993;37:2443-2448.
15. LaRocco M. Recent developments in antifungal susceptibility testing. Clin Microbiol Newsletter 1991;13:81-85.
16. Carrillo-Muñoz AJ, Abarca-Salat L, Quindós G. Pruebas de estudio de sensibilidad a los antifúngicos. I Factores que influyen en su realization en el laboratorio. Rev Iberoam Micol 1994;11:77-80.
17. National Committee for Clinical Laboratory Standards. Antifungal susceptibility testing; Committee report. NCCLS document M-20-CR NCCLS 771 E Lancaster Ave, Villanova, Pennsylvania, 1935.
18. Sabaté, M, Torres-Rodríguez JM, Gallach C, Madrenys N, Carrillo-Muñoz AJ. Valor de la difusión en agar trente a la concentración mínima inhibitoria en el estudio de la sensibilidad a tres antifungicos en Candida sp y Torulopsis glabrala. Rev Esp Microbiol Clin 1991;6:229-232.
19. Quindós G, Salesa R, Carrillo-Muñoz AJ, et al. Multicenter evaluation of ATB-fungus: A standardized micromethod for yeast susceptibility testing. Chemother 1994;40:245-251.
20. Pontón J, Torres-Rodríguez JM, Salesa R, et al. Evaluación del Candifast. un nuevo método para la identificación y estudio de la sensibilidad antifúngica de las levaduras de interes médico Rev Iberoam Micol 1994;11:64-67
21. Carrillo-Muñoz AJ. Evaluación multicentrica de la reproductibilidad del antifungigrama NeoSensitabs sensitivity testing. Rev Iberoam Micol 1994;11:56.
22. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39:314-319.
23. Odds FC, Vrancks L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 1995;39:2051-2060
24. Torres-Rodríguez JM, Sabat, M, Gallach C, Carrillo-Muñoz AJ, Madrenys N. Sensibilidad in vitro a la 5-fluorocitosma y anfoterícina B de levaduras del género Candida aisladas en Barcelona. Enferm Infec Microbiol Clin 1990;8:91-93.
25. Espinel-Ingroff A, Shadomy S, White S. Agar diffusion susceptibility tests with cilofungin (LY-121019). J Med Vet Mycol 199129:93-98.
26. Drouhet E, Dupont B, Improvisi L, Viviani MA, Tortorano AM Disc agar diffusion and microplate automated technics for in vitro evaluation of antifungal agents on yeats and sporulated pathogenic fungi. En Iwata K, y Vanden Bossche H (Eds). In vitro and in vivo evaluation of antifungal agents. Amsterdam. Elsevier, 1986:31-48.
27. Scholar HJ, Polak AM. Resistance to systemic antifungal agents. Antimicrobial drug resistance 1984;23:393-460.
28. Kerridge D, Vanden Bossche H. Drug discovery: a biochemist approach En Ryley JF (Ed), Handbook of experimental Pharmacology, vol 96. Chemotherapy of fungal diseases Berlin, Springer Verlag, 1990:31-76.
29. Currie B, Sandi H, Ibrahim A, Edwards JE, Casadevall A, Gahnnoum MA. Sterol composition amd susceptibility to amphotericin B of enviromental Cryptococcus neoformans are changed by murine passage. Antimicrob Agents Chemother 1995;39:1934-1937.
30. Odds FC. Antifungal agents and their use in Candida infections. En Odds FC. Candida and Candidosis. A review and bibliography. London, Bailliere Tindall, 1988.
31. Kerridge D, Nicholas RD. Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata. J Antimicrob Chemother 1986;18:39-49.
32. Sugar AM. Use of amphotericin B with azole antifungal drugs. What are we doing? Antimicrob Agents Chemother 1995;39:1907-1912.
33. Arévalo P, Arias A, Andreu A, Sierra A. Sensibilidad de 278 aislados de Candida albicans trente a anfotericina B, fluconazol e itraconazol Rev Iberoam Micol 1992;9:94-96
34. Muller J. Resistezphanomene bei systemisch wirksamen antimykotika und das problem der empfindl ichkeitdptufung. Mycoses 1992;35 (suppl):1-7.
35. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
36. Polak A. Mode of action studies. En Ryley JF (Ed). Handbook of experimental pharmacology. Chemotherapy of fungal diseases. Berlin, Springer Verlag, 1990:153-182.
37. Johnson EM, Richardson MD, Warnock DW. In vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemoter 1984;13:547-558.